Ibrutinib and ublituximab – a promising combination regimen for treating CLL?
How can we overcome ibrutinib resistance?
Do CLL patients with mutated immunoglobulin receptors respond better to therapy?
Advances in the treatment of chronic lymphocytic leukemia
The role of Richter’s syndrome in determining the prognosis of CLL patients